====== Amgen ======
**Amgen Inc.** is a multinational biopharmaceutical company headquartered in Thousand Oaks, California, primarily focused on drug discovery, development, and commercialization. The company operates across therapeutic areas including oncology, cardiovascular disease, inflammation, and bone health, with a strong emphasis on leveraging advanced computational and artificial intelligence technologies to accelerate research and development processes.

===== Overview =====
Amgen stands as one of the world's largest independent biotechnology firms, with extensive operations in drug manufacturing, clinical research, and translational medicine. The company has demonstrated significant commitment to integrating cutting-edge artificial intelligence and machine learning technologies into its research infrastructure to enhance drug discovery efficiency and reduce development timelines (([[https://www.amgen.com|Amgen Official Website]])).

The organization maintains research and development facilities globally and employs thousands of scientists, researchers, and technical specialists dedicated to identifying and developing novel therapeutic interventions for serious diseases.

===== AI and Machine Learning Integration =====
Amgen has adopted advanced computational tools for accelerating drug discovery and translational medicine research. The company has implemented trusted-access deployment of specialized AI systems, including **[[gpt_rosalind|GPT-Rosalind]]**, an AI platform designed specifically for pharmaceutical research applications (([[https://www.theneurondaily.com/p/two-free-3d-world-models-dropped-this-week|The Neuron - April 2026]])).

The integration of large language models and machine learning approaches enables Amgen researchers to:

* Accelerate molecular screening and compound identification
* Enhance understanding of disease mechanisms through computational analysis
* Optimize translational medicine workflows from basic research to clinical application
* Process and analyze complex biomedical literature and research data
* Support hypothesis generation and experimental design

This deployment represents a strategic commitment to computational drug discovery methodologies that complement traditional laboratory-based research approaches (([[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171572/|National Center for Biotechnology Information - AI in Drug Discovery (2021]])).

===== Therapeutic Focus Areas =====
Amgen's research and development portfolio spans multiple disease areas with particular emphasis on conditions affecting aging populations and patients with limited treatment options. The company's pipeline includes biologics and small-molecule therapeutics targeting cancer, bone loss, cardiovascular conditions, and inflammatory diseases.

The use of computational approaches and AI-assisted analysis has become integral to evaluating therapeutic targets and optimizing drug candidates across these disease domains (([[https://pubmed.ncbi.nlm.nih.gov/29424356/|PubMed - Machine Learning Applications in Pharmaceutical Development]])).

===== Drug Discovery and Development Process =====
Amgen's drug development pipeline incorporates multiple stages from basic research through clinical trials to regulatory approval. The company maintains manufacturing capabilities for both small-molecule and biologic therapeutics, with quality control systems meeting stringent pharmaceutical standards.

The incorporation of AI tools like GPT-Rosalind supports researchers throughout the discovery pipeline by enabling rapid analysis of large datasets, identification of promising drug candidates, and assessment of potential safety and efficacy profiles before advancing to preclinical and clinical testing phases.

===== Research Infrastructure and Partnerships =====
The company operates through a combination of internal research capabilities and strategic collaborations with academic institutions, biotechnology partners, and technology providers. These partnerships extend Amgen's access to specialized expertise and emerging technologies in computational biology, bioinformatics, and artificial intelligence applications.

Amgen's commitment to modernizing research infrastructure reflects broader industry trends toward data-driven and computationally-assisted drug discovery methodologies (([[https://www.nature.com/articles/s41587-021-01056-6|Nature Biotechnology - AI in Drug Development (2021]])).


===== See Also =====

  * [[heygen|HeyGen]]
  * [[amd|AMD]]
  * [[bessemer_venture_partners|Bessemer Venture Partners]]

===== References =====
* https://www.amgen.com
* https://www.theneurondaily.com/p/two-free-3d-world-models-dropped-this-week
* https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171572/
* https://pubmed.ncbi.nlm.nih.gov/29424356/
* https://www.nature.com/articles/s41587-021-01056-6